Clinical Trial Search

Primary: LS Mean Sleep Efficiency (SE) During Periods 1 and 2 — 75.8; 81.0; 83.4; 86.6 percent of time in bed — p=<0.001

Primary: Overall Survival (OS) — 19.8 months

Primary: Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months — 2.56 percentage of participants — p=<0.0001

Primary: Computed Tomography Evidence of Less Sinus Disease — 5.875; 3 units on a scale — p=0.2

Primary: Maximum Tolerated Dose, Dose Limiting Toxicity — 0; 0; 0; 0 participants

Primary: Percentage of Subjects Avoiding Any Allogeneic Transfusions for Seven Days Post-operative or Until Discharge, Whichever Came First — 35.2; 35.7; 34.1; 64.8 percentage…

Primary: Participant Responses — 2; 8; 4; 6 participants

Primary: Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 16 — 5.7; 11.2; 28.7; 40.9…

Primary: Percentage of Participants With Disease Progression or Death — 72.1; 76.2 percentage of participants

Primary: Percentage of Participants With Pathological Complete Response (pCR) — 24.2 percentage of participants

Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients

Primary: Physical Function as Measured by Telephone Version of FIM — 83.7; 80.9 units on a scale

Primary: Drinking — 6; 8; 2 participants — p=<0.04

Primary: Index Knee Pain Scores on a Numeric Rating Scale (NRS) — 4.167; 4.703 units on a scale

Primary: Pain Score, Visual Analogue Pain Scores — 1.9 units on a scale